Patents by Inventor Kristie Vanpatten

Kristie Vanpatten has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Grading, staging, and prognosing cancer using osteopontin-c
    Patent number: 10934591
    Abstract: The present disclosure provides methods and kits that can be used to determine the grade or stage of a breast or other cancer, such as a ductal carcinoma in situ (DCIS). By determining the grade, stage, or aggressiveness of a cancer, appropriate therapeutic regiments can be selected and administered to the patient with the cancer. The method includes detecting osteopontin-c (OPN-c), wherein the presence of high amounts of OPN-c in the cancer sample indicates that the subject has a more aggressive form of cancer (e.g., grade 3).
    Type: Grant
    Filed: December 13, 2017
    Date of Patent: March 2, 2021
    Assignees: VENTANA MEDICAL SYSTEMS, INC., UNIVERSITY OF CINCINNATI
    Inventors: Mana Mirza, Elizabeth Shaughnessy, John K. Hurley, Kristie A. Vanpatten, Gary Pestano, Georg F. Weber
  • Expression of ETS related gene (ERG) and phosphatase and tensin homolog (PTEN) correlates with prostate cancer capsular penetration
    Patent number: 10407736
    Abstract: The disclosure provides methods for characterizing a prostate cancer sample by detecting expression of ERG, PTEN or both, changes in which relative to a normal control are shown herein to be correlated with prostate cancer capsular penetration and more aggressive forms of prostate cancer. Such methods are useful for the prognosis of prostate cancer capsular penetration and for making treatment decisions in patients with prostate cancer that has penetrated the capsule. Also provided are kits that can be used with such methods.
    Type: Grant
    Filed: August 19, 2016
    Date of Patent: September 10, 2019
    Assignees: Ventana Medical Systems, Inc., The Arizona Board of Regents on behalf of the University of Arizona
    Inventors: Gary Pestano, Ray B. Nagle, Connie Cortez, Kristie A. Vanpatten, Amit M. Algotar
  • GRADING, STAGING, AND PROGNOSING CANCER USING OSTEOPONTIN-C
    Publication number: 20180119232
    Abstract: The present disclosure provides methods and kits that can be used to determine the grade or stage of a breast or other cancer, such as a ductal carcinoma in situ (DCIS). By determining the grade, stage, or aggressiveness of a cancer, appropriate therapeutic regiments can be selected and administered to the patient with the cancer. The method includes detecting osteopontin-c (OPN-c), wherein the presence of high amounts of OPN-c in the cancer sample indicates that the subject has a more aggressive form of cancer (e.g., grade 3).
    Type: Application
    Filed: December 13, 2017
    Publication date: May 3, 2018
    Inventors: Mana Mirza, Elizabeth Shaughnessy, John K. Hurley, Kristie A. Vanpatten, Gary Pestano, Georg F. Weber
  • Grading, staging and prognosing cancer using osteopontin-C
    Patent number: 9873915
    Abstract: The present disclosure provides methods and kits that can be used to determine the grade or stage of a breast or other cancer, such as a ductal carcinoma in situ (DCIS). By determining the grade, stage, or aggressiveness of a cancer, appropriate therapeutic regiments can be selected and administered to the patient with the cancer. The method includes detecting osteopontin-c (OPN-c), wherein the presence of high amounts of OPN-c in the cancer sample indicates that the subject has a more aggressive form of cancer (e.g., grade 3).
    Type: Grant
    Filed: October 16, 2008
    Date of Patent: January 23, 2018
    Assignees: Ventana Medical Systems, Inc., University of Cincinnati
    Inventors: Mana Mirza, Elizabeth Shaughnessy, Georg F. Weber, John K. Hurley, Kristie A. Vanpatten, Gary Pestano
  • EXPRESSION OF ETS RELATED GENE (ERG) AND PHOSPHATASE AND TENSIN HOMOLOG (PTEN) CORRELATES WITH PROSTATE CANCER CAPSULAR PENETRATION
    Publication number: 20160355891
    Abstract: The disclosure provides methods for characterizing a prostate cancer sample by detecting expression of ERG, PTEN or both, changes in which relative to a normal control are shown herein to be correlated with prostate cancer capsular penetration and more aggressive forms of prostate cancer. Such methods are useful for the prognosis of prostate cancer capsular penetration and for making treatment decisions in patients with prostate cancer that has penetrated the capsule. Also provided are kits that can be used with such methods.
    Type: Application
    Filed: August 19, 2016
    Publication date: December 8, 2016
    Applicants: Ventana Medical Systems, Inc., The Arizona Board of Regents on behalf of the University of Arizona
    Inventors: Gary Pestano, Ray B. Nagle, Connie Cortez, Kristie A. Vanpatten, Amit M. Algotar
  • Expression of ETS related gene (ERG) and phosphatase and tensin homolog (PTEN) correlates with prostate cancer capsular penetration
    Patent number: 9435812
    Abstract: The disclosure provides methods for characterizing a prostate cancer sample by detecting expression of ERG, PTEN or both, changes in which relative to a normal control are shown herein to be correlated with prostate cancer capsular penetration and more aggressive forms of prostate cancer. Such methods are useful for the prognosis of prostate cancer capsular penetration and for making treatment decisions in patients with prostate cancer that has penetrated the capsule. Also provided are kits that can be used with such methods.
    Type: Grant
    Filed: August 28, 2012
    Date of Patent: September 6, 2016
    Assignees: Ventana Medical Systems, Inc., The Arizona Board of Regents on behalf of the University of Arizona
    Inventors: Gary Pestano, Ray B. Nagle, Connie Cortez, Kristie A. Vanpatten, Amit M. Algotar
  • EXPRESSION OF ETS RELATED GENE (ERG) AND PHOSPHATASE AND TENSIN HOMOLOG (PTEN) CORRELATES WITH PROSTATE CANCER CAPSULAR PENETRATION
    Publication number: 20130196866
    Abstract: The disclosure provides methods for characterizing a prostate cancer sample by detecting expression of ERG, PTEN or both, changes in which relative to a normal control are shown herein to be correlated with prostate cancer capsular penetration and more aggressive forms of prostate cancer. Such methods are useful for the prognosis of prostate cancer capsular penetration and for making treatment decisions in patients with prostate cancer that has penetrated the capsule. Also provided are kits that can be used with such methods.
    Type: Application
    Filed: August 28, 2012
    Publication date: August 1, 2013
    Inventors: Gary Pestano, Ray B. Nagle, Connie Cortez, Kristie A. Vanpatten, Amit M. Algotar
  • Grading, Staging and prognosing Cancer using Osteopontin-C
    Publication number: 20100209928
    Abstract: The present disclosure provides methods and kits that can be used to determine the grade or stage of a breast or other cancer, such as a ductal carcinoma in situ (DCIS). By determining the grade, stage, or aggressiveness of a cancer, appropriate therapeutic regiments can be selected and administered to the patient with the cancer. The method includes detecting osteopontin-c (OPN-c), wherein the presence of high amounts of OPN-c in the cancer sample indicates that the subject has a more aggressive form of cancer (e.g., grade 3).
    Type: Application
    Filed: October 16, 2008
    Publication date: August 19, 2010
    Inventors: Mana Mirza, Elizabeth Shaughnessy, Georg F. Weber, John K. Hurley, Kristie A. Vanpatten, Gary Pestano
  • Predictive Methods For Cancer Chemotherapy
    Publication number: 20070031902
    Abstract: This invention provides methods and reagents for determining or predicting response to cancer therapy, as well as dual therapy treatments.
    Type: Application
    Filed: August 3, 2006
    Publication date: February 8, 2007
    Inventors: Gary Pestano, Linda Samadzadeh, Kristie Vanpatten